December 3, 2020
Olaparib Granted Positive EU Opinion for BRCA1/2+ Advanced Prostate Cancer BookmarkGeorge Lundberg, MD
A news story published by OncLive reports that the European Union’s Committee for Medicinal Products for Human Use recently approved the drug olaparib for treating patients with a subset of advanced castrate-resistant prostate cancers that have BRCA1/2 mutations.
September 18, 2018
Biomarkers, PARP Inhibitors Vital for Personalized Treatment in Breast Cancer Subtypes BookmarkEmma Shtivelman, PhD
Excerpt from OncLive:
“Developing predictive biomarkers will be key to treating patients with triple-negative breast cancer (TNBC), especially when choosing a targeted therapy, said Banu K. Arun, MD.
“In a presentation during the 2018 OncLive® State of the Science Summit™ on Breast Cancer, Arun said there is evidence that PARP inhibitors as well as immunotherapy in combination with various agents may be effective in women with TNBC and BRCA1-related breast cancers, but the science isn’t there yet.”
Go to full article published by OncLive on Aug 29, 2018.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.